8-K: TRSO Acquires XRS, Expands into AI-TCM Health Tech

Transuite.Org Inc. (TRSO) has acquired Xirangsheng (Shenzhen) Health Technology Co., Ltd. (XRS), a company specializing in AI-driven Traditional Chinese Medicine (TCM) health solutions, marking a strategic expansion into the health tech sector.

Summary

• TRSO acquired 100% of Xirangsheng (Shenzhen) Health Technology Co., Ltd. (XRS) through its wholly-owned subsidiary, Crestar Holdings Limited.
• XRS is an innovative enterprise combining AI Social Agent technology with Traditional Chinese Medicine (TCM), focused on building a 'self-medical concept + self-medical method + health supervision system' ecology.
• XRS's core products include AI Social Agents based on a massive TCM knowledge base, a 21-day health supervision system, and 300 series of proprietary TCM health e-books with independent intellectual property certifications.
• Initial consideration for the acquisition was 10,000,000 restricted shares of TRSO common stock issued to Hailiang Li, the seller.
• An earnout provision allows for additional shares to be issued based on an independent valuation of XRS, to be completed within 90 days after closing.
• Additional shares will be calculated using the formula: (XRS Valuation / TRSO's closing price on September 30, 2025) 10,000,000 initial shares.
• The acquisition aims to integrate TRSO's strengths in AI and blockchain technology with XRS's TCM AI technology and content ecosystem to promote TCM globally and accelerate XRS's international business expansion.

Sentiment

Score: 7

Explanation: The acquisition is strategically positive, expanding TRSO into a high-growth sector with proprietary intellectual property and global expansion potential. However, the immediate dilution from initial share issuance and potential future earnout shares, coupled with the uncertainty of XRS's valuation, introduces some caution.

Positives

• Strategic expansion into the high-growth AI-powered healthcare technology sector, specifically Traditional Chinese Medicine (TCM).
• Acquisition of proprietary intellectual property, including 300 series of TCM health e-books with global copyright protection in over 180 countries.
• Leveraging TRSO's AI and blockchain capabilities to enhance XRS's product intelligence and platform services, potentially accelerating global expansion.
• XRS's 'Super IP Li Ziyi' based on a vast TCM knowledge base aims to serve global users in multiple languages through major social platforms, offering 'One Person, One Recipe' accurate health management services.
• Diversified profit models for XRS content, applicable to health consultation, education and training, intelligent hardware, and government health projects.

Negatives

• Issuance of 10,000,000 restricted common shares as initial consideration, which could lead to dilution for existing shareholders.
• Potential for further dilution through an earnout provision based on XRS's independent valuation, with additional shares to be issued.
• The exact valuation of XRS and the number of additional shares to be issued are yet to be determined, creating uncertainty regarding the total acquisition cost and dilution impact.
• The acquisition involves a company based in Shenzhen, China, which may introduce geopolitical or regulatory risks associated with international operations and data privacy.

Risks

• Forward-looking statements are subject to risks and uncertainties, including those concerning future business results, financial condition, and liquidity.
• Risks associated with the independent valuation of XRS and the calculation of additional shares, as it relies on a third-party firm and TRSO's historical stock price.
• Integration risks of combining TRSO's AI and blockchain technology with XRS's TCM AI technology and content ecosystem.
• Regulatory compliance risks related to federal and state securities laws for share issuance and international business operations.
• Potential for material adverse changes in XRS's business, financial condition, operations, or prospects before the valuation is finalized and integration is complete.

Future Outlook

TRSO plans to deeply integrate its AI and blockchain technology with XRS's AI-TCM solutions to promote Traditional Chinese Medicine globally, develop more AI and health products, and create a smarter, more trustworthy, and convenient health management ecosystem for users. XRS aims to accelerate its global business expansion by leveraging TRSO's international capital market access and technological capabilities, enhancing its product intelligence and platform services.

Management Comments

• Mengqing Fan, CEO of TRSO, stated: "We are very glad to partner with XRS. As innovators combining Traditional Chinese Medicine and AI, they show unique competitiveness in self-medical concept, AI health supervision and digital Chinese medicine content. Through this full acquisition, we will deeply integrate our strengths in AI and blockchain technology to help XRS to promote the ancient wisdom of Traditional Chinese Medicine to worldwide, develop more AI and healthy products, and create greater value for shareholders and customers. We believe this will be a significant milestone for AI empowering Traditional Chinese Medicine and promote globalization."
• Hailiang Li, CEO of XRS, commented: "We are honored to reach this acquisition with TRSO. Their globally leadership in AI and blockchain will provide us with strong technological and global market support. Through this collaboration, we will not only further consolidate our innovative edge in the field of digital health in China, but also gain the opportunity to promote the TCM AI self-care platform worldwide. We look forward to working with TRSO to build a smarter, more trustworthy, and convenient health management ecosystem for users, jointly leading the future development of global intelligent health."

Industry Context

This acquisition positions TRSO at the intersection of two rapidly growing sectors: AI-driven healthcare technology and the global wellness market, particularly Traditional Chinese Medicine (TCM). The integration of AI with TCM aligns with broader trends of digital transformation in healthcare, personalized medicine, and the increasing demand for holistic health solutions. Competitors in the digital health space are increasingly incorporating AI for diagnostics, personalized treatment plans, and patient engagement, while the global TCM market is expanding due to rising consumer interest in natural and alternative therapies.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential dilution from the initial issuance of 10,000,000 restricted shares and further dilution from earnout shares. Potential for increased shareholder value through strategic expansion into a high-growth market.
• Employees (XRS): Integration into a larger, publicly traded company with access to advanced AI and blockchain technologies, potentially offering new growth opportunities.
• Customers (XRS): Expected to benefit from enhanced product intelligence, platform services, and broader global reach for the TCM AI self-care platform.
• Management (TRSO & XRS): New strategic direction and integration challenges, requiring effective collaboration to realize synergies.

Next Steps

• An independent, qualified valuation firm will prepare a comprehensive valuation report of XRS within 90 days after the closing date (September 30, 2025).
• TRSO will issue additional common shares to the seller within 60 days after receipt of the final Valuation Report, subject to Board approval and compliance with applicable securities laws.
• XRS shall conduct its business in the ordinary course consistent with past practice until the Valuation Report is completed.
• TRSO will receive monthly financial reports from XRS and inspect XRS's books and records upon reasonable advance notice.
• Crestar shall be entitled to appoint a majority of XRS's board of directors and exercise all voting rights as directed by TRSO's Board of Directors.

Key Dates

Recommendation

The acquisition of XRS represents a significant strategic move for TRSO into the high-growth AI-driven health tech and Traditional Chinese Medicine sectors, leveraging proprietary intellectual property and global expansion potential. This could drive long-term value. However, the immediate dilution from the initial 10,000,000 restricted share issuance and the potential for further dilution via the earnout provision, whose value is yet to be independently determined, introduces short-term uncertainty. A 'hold' recommendation is appropriate until the full valuation of XRS is completed and the impact of potential additional share issuances is clearer, allowing investors to assess the true cost and long-term benefits more accurately.

Keywords

AI health tech, Traditional Chinese Medicine, TCM, AI Social Agent, Healthcare technology, Merger & Acquisition, Share Exchange, Digital health, Blockchain, Web3, Shenzhen